Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Conversant Inc. (NASDAQ: CNVR) shares surged 17.07 percent to close at $25.45 a share Wednesday. The stock traded between $24.44 and $26.42 on volume 3.92 million shares traded. The company reported non-GAAP net income per diluted share was $0.67 for the fourth quarter of 2013, an increase of 43.0 percent when compared to a year ago. Shares of Conversant are up approximately 9.0 percent year-to-date.
Get more information on Conversant and free access to the in-depth equity report at:
DaVita HealthCare Partners Inc. (NYSE: DVA) shares increased 3.14 percent to close at $66.35 a share Wednesday. The stock traded between $66.30 and $68.84 on volume 4.43 million shares traded. The company reported total U.S. dialysis treatments were 6,106,166 for the fourth quarter of 2013, an increase of 6.3 percent per day when compared to a year ago. Shares of DaVita are up approximately 5.0 percent year-to-date.
Get more information on DaVita free access to the in-depth equity report at:
Jive Software Inc. (NASDAQ: JIVE) shares dropped 18.83 percent to close at $7.20 a share Wednesday. The stock traded between $7.20 and $8.26 on volume of 5.27 million shares traded. The company’s first quarter forecast of revenues in the range of $40 million to $41 million, and a net loss of $0.11 to $0.13, fell short of average analysts’ estimates of $41.3 million and a loss of $0.12. Shares of Jive Software are down approximately 36.0 percent year-to-date.
Get more information on Jive Software and free access to the in-depth equity report at:
Seattle Genetics, Inc. (NASDAQ: SGEN) shares spiked 10.72 percent to close at $50.49 a share Wednesday. The stock traded between $47.13 and $51.97 on volume of 4.02 million shares traded. The company reported revenues were $67.4 million for the fourth quarter of 2013, compared to $63.9 million a year ago. Shares of Seattle Genetics are up approximately 26.0 percent year-to-date.
Get more information on Seattle Genetics and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities
Leave a comment...